Schaal K P, Pape W
Infection. 1980;8 Suppl 2:S176-82. doi: 10.1007/BF01639887.
Knowledge on the antibiotic suceptibility of pathogenic fermentative actinomycetes is still fragmentary and contradictory, which is one reason why even today the chemotherapy of human actinomycosis may still present problems. Complete and reliable data on the in vitro sensitivity of these pathogens can be obtained, however, when standardized and specially adapted methods of susceptibility testing are employed. Special adaptation should cover the general technique of in vitro testing, as well as the choice of test media, the preparation of inocula, incubation methods and method of reading results. Provided that all factors are taken into account which might cause difficulties in test reproducibility and therapeutic relevance of the results, in vitro tests appear to contribute to the revision and updating of treatment regimes for actinomycosis. Our findings indicate that, apart from ampicillin the clinical efficacy of which has already often been proved, mezlocillin, cefoxitin, clindamycin, tetracyclines, rifampicin and erythromycin may be recommended as alternative drugs which would seem to offer good chances of success.
关于致病性发酵放线菌对抗生素的敏感性的知识仍然零碎且相互矛盾,这就是为什么即使在今天,人类放线菌病的化疗可能仍然存在问题的原因之一。然而,当采用标准化且经过特殊调整的药敏试验方法时,可以获得关于这些病原体体外敏感性的完整且可靠的数据。特殊调整应涵盖体外试验的一般技术,以及试验培养基的选择、接种物的制备、培养方法和结果读取方法。只要考虑到所有可能导致试验可重复性困难和结果治疗相关性的因素,体外试验似乎有助于放线菌病治疗方案的修订和更新。我们的研究结果表明,除了其临床疗效已多次得到证实的氨苄西林外,美洛西林、头孢西丁、克林霉素、四环素、利福平和红霉素可作为替代药物推荐,似乎有很大的成功机会。